Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky

Bright Minds Biosciences (DRUG) shares sold off sharply as the market reacted to an FDA partial clinical hold on the planned Phase 2 BMB-101 pediatric epilepsy trial. An investigation into potential securities law violations is underway on behalf of investors who lost money.

NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Bright Minds Biosciences (NASDAQ: DRUG) shares were hit by a sharp selloff after the FDA placed the Company's planned Phase 2 BMB-101 pediatric epilepsy trial on partial clinical hold, citing toxicity findings in mice. If your DRUG shares lost value in that selloff, you are encouraged to submit your DRUG loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Bright Minds stated that the hold was limited to the planned U.S. study and did not affect its other ongoing trials. The Company also said it disagreed with the FDA's interpretation of the mouse findings. That disagreement did not resolve the agency's concerns, which also covered insufficient pharmacokinetic and juvenile-toxicity data to support pediatric enrollment.

Bright Minds said it was still awaiting the FDA's full letter. It also acknowledged that additional data or studies might be required. The hold left the trial's design, timing, and regulatory path uncertain. Levi & Korsinsky is investigating potential securities law violations on behalf of DRUG investors who suffered losses.

DRUG shareholders who lost money in the selloff can start a free review of their losses or call (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the DRUG Investigation

Q: How much did DRUG stock drop?A: Bright Minds Biosciences shares sold off sharply after the Company disclosed that the FDA had placed its planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. The FDA cited toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Bright Minds Biosciences made materially false or misleading statements about the preclinical safety profile of BMB-101 and its planned pediatric Phase 2 trial. When the Company disclosed the FDA's partial clinical hold, the stock price declined sharply.

Q: When did Bright Minds Biosciences allegedly mislead investors?A: The investigation concerns statements made before the disclosure of the FDA's partial clinical hold. These statements allegedly caused investors to purchase DRUG securities at inflated prices.

Q: What do DRUG investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my DRUG shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought DRUG and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis. Any attorneys' fees and expenses are subject to court approval.

Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP